Aviv Regev, Ph.D.

Aviv Regev, Ph.D., is head and Executive Vice President of Genentech Research and Early Development. Formerly, Regev was Chair of the Faculty and Core Member at the Broad Institute of MIT and Harvard, Professor of Biology at MIT, and a Howard Hughes Medical Institute Investigator. She is founding co-chair of the Human Cell Atlas and a leader in deciphering molecular circuits that govern cells, tissues, and organs in health and their malfunction in disease. She has pioneered foundational experimental and computational methods in single-cell genomics, enabling greater understanding of cell and tissue functions.

Regev is a member of the National Academy of Sciences, National Academy of Medicine, American Academy of Arts and Sciences, and a Fellow of the International Society of Computational Biology (ISCB). Her many honors include the ISCB Overton and Innovator Prizes, Paul Marks Prize, Lurie Prize in Biomedical Sciences, Keio Medical Science Prize, HFSP Nakasone Award, and L'Oréal-UNESCO for Women in Science Award.

Serena Silver, Ph.D.

Serena Silver, Ph.D., is the Chief Scientific Officer at Accent Therapeutics (Lexington, MA, USA), a clinical-stage biotechnology company that aims to translate extraordinary science into life-changing therapeutics for patients living with cancer. Prior to joining Accent, Serena served as Vice President of Discovery Biology and Technologies at Fulcrum Therapeutics, where she led scientific teams to develop and deploy new assay modalities and complex cellular models of disease to identify targets and discover therapeutics for rare diseases. Previously, Serena led the Molecular Pharmacology group at Novartis Oncology, the Target ID & Validation team at Sanofi Oncology, and worked at the forefront of functional genomics screening technology at the Broad Institute. Dr. Silver earned a Ph.D. in Biology from the Massachusetts Institute of Technology and completed a postdoctoral fellowship at Harvard Medical School.